Furthermore, CDK4/6 inhibitors and PIK3CA inhibitors are standard of care for advanced luminal carcinomas, and as mentioned above, ERBB2-low expression has been recently reported as an independent predictor of inferior progression-free survival [30]. Here, ERBB2 is linked to carcinoma.